Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00769587|
Recruitment Status : Completed
First Posted : October 9, 2008
Last Update Posted : April 26, 2016
RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease.
PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive systemic mastocytosis.
|Condition or disease||Intervention/treatment||Phase|
|Non Neoplastic Condition Precancerous Condition||Drug: thalidomide||Phase 2|
- Determine the objective response rate at 6 months in patients with systemic mastocytosis treated with thalidomide.
- Determine the tolerability of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral thalidomide once daily for 6 months in the absence of disease progression.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Thalidomide in Mastocytosis|
|Study Start Date :||June 2007|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||October 2012|
Use of thalidomide
- Objective reduction of the infiltration rate at 6 months [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00769587
|Centre Hospitalier Universitaire d'Amiens|
|Amiens, France, 80054|
|Study Chair:||Gandhi Damaj||Centre Hospitalier Universitaire, Amiens|